Forbion, Morningside Ventures and Ascendant BioCapital have led a $196m series-A funding round for Dutch clinical-stage biotechnology company NewAmsterdam Pharma (NAP).
Forbion, Morningside Ventures and Ascendant BioCapital have led a $196m series-A funding round for Dutch clinical-stage biotechnology company NewAmsterdam Pharma (NAP).